Bladder cancer

Objectif pédagogique: Gain insight on individual treatment strategies for (very) high-risk non-muscle-invasive bladder cancer (NMIBC) in Bacillus Calmette-Guérin (BCG) naïve patients and after BCG failure.

Spécialité: Urology, Medical oncology

Public cible: CME (basic, intermediate), Residents (senior)

Dernière mise à jour: May 2022

Contexte:

The EAU and AUA/SUO guidelines recommend the stratification of patients with NMIBC into risk groups based on their probability of progression to muscle-invasive disease [1,2].

The EAU risk stratification consists of 4 risk groups (low, intermediate, high and very high) and takes into account, on top of stage and grade, the following clinical risk factors [1]:

• Age >70 years
• Multiple papillary tumours
• Tumour diameter >3 cm

Meanwhile, the AUA risk stratification for NMIBC consists of 3 risk groups (low, intermediate and high) [2].

(Very) High-risk NMIBC according to the EAU and AUA guidelines

Regulatory approval status of drugs for high-risk BCG-unresponsive NMIBC (status 1 December 2021)

 

1. Babjuk M, Burger M, Compérat E, et al. European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Update March 2022. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
2. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline. Update 2020. Available at: https://www.auanet.org/guidelines/guidelines/bladder-cancer-non-muscle-invasive-guideline